By modifying the epidermal growth factor receptor and folate hydrolase 1 (PSMA) of bi-specific antibodies on the LNP surface, they were able to achieve mRNA expression in tumor tissues with an ∼8-fold increase compared to untargeted modifications in vivo. This evidence concerns the gene FOLH1 and neoplasm.